Association between the methylation status of the MGMT promoter in bone marrow specimens and chemotherapy outcomes of patients with acute myeloid leukemia

Hong,Qingxiao; Chen,Xiaoying; Ye,Huadan; Zhou,Annan; Gao,Yuting; Jiang,Danjie; Wu,Xiaodong; Tian,Bingru; Chen,Youfen; Wang,Ming; Xie,Jiping; Xia,Yongming; Duan,Shiwei

doi:10.3892/ol.2016.4317

Association between the methylation status of the MGMT promoter in bone marrow specimens and chemotherapy outcomes of patients with acute myeloid leukemia

Authors:
- Qingxiao Hong
- Xiaoying Chen
- Huadan Ye
- Annan Zhou
- Yuting Gao
- Danjie Jiang
- Xiaodong Wu
- Bingru Tian
- Youfen Chen
- Ming Wang
- Jiping Xie
- Yongming Xia
- Shiwei Duan
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, P.R. China, Department of Hematology, Yuyao People's Hospital, Yuyao, Zhejiang 315400, P.R. China
Published online on: March 9, 2016 https://doi.org/10.3892/ol.2016.4317
Pages: 2851-2856

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The O(6)-methylguanine-DNA methyltransferase (MGMT) gene is a tumor suppressor gene that is associated with the risk of developing acute myeloid leukemia (AML). However, the association between the methylation status of the MGMT promoter and the chemotherapeutic outcomes of patients with AML remains unknown. In the present study, 30 bone marrow samples derived from patients with AML were collected prior and subsequent to chemotherapy. The methylation status of the MGMT promoter in the bone marrow specimens was determined by methylation‑specific polymerase chain reaction. The results indicated that the methylation status of the MGMT promoter was influenced by different chemotherapeutic regimens. The MGMT methylation status of M4 patients (3 out of 6) were more chemosensitive, compared with that of patients with other AML subtypes (M1, 1 out of 3; M2, 0 out of 8; M3, 3 out of 7; M5, 0 out of 3; and M6, 1 out of 3). Age‑based analysis revealed that the group aged ≤60 years (7 out of 24 patients) exhibited more methylation changes than patients aged >60 years (1 out of 6). Male patients (4 out of 13) were more susceptible to chemotherapy‑induced methylation changes than female patients (4 out of 17). Thus, the methylation status of the MGMT promoter may serve as a potential biomarker to predict the therapeutic outcomes in male AML patients. However, further studies in larger sample sets are required to confirm the present findings.

View Figures

View References

1	Estey EH: Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol. 88:318–327. 2013. View Article : Google Scholar : PubMed/NCBI
2	Davis AS, Viera AJ and Mead MD: Leukemia: An overview for primary care. Am Fam Physician. 89:731–738. 2014.PubMed/NCBI
3	Thein MS, Ershler WB, Jemal A, Yates JW and Baer MR: Outcome of older patients with acute myeloid leukemia: An analysis of SEER data over 3 decades. Cancer. 119:2720–2727. 2013. View Article : Google Scholar : PubMed/NCBI
4	Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, Pavlu J, Brisley G, de Lavallade H, Sarvaria A, et al: Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 99:836–847. 2014. View Article : Google Scholar : PubMed/NCBI
5	Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E, Lunghi M, D'Arco AM, Levis A, Pastore D, et al: Azacitidine for the treatment of patients with acute myeloid leukemia: Report of 82 patients enrolled in an Italian Compassionate Program. Cancer. 118:1014–1022. 2012. View Article : Google Scholar : PubMed/NCBI
6	Boultwood J and Wainscoat JS: Gene silencing by DNA methylation in haematological malignancies. Br J Haematol. 138:3–11. 2007. View Article : Google Scholar : PubMed/NCBI
7	Tuominen R, Jewell R, van den Oord JJ, Wolter P, Stierner U, Lindholm C, Johansson Hertzman C, Lindén D, Johansson H, Frostvik Stolt M, et al: MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. Int J Cancer. 136:2844–2853. 2015. View Article : Google Scholar : PubMed/NCBI
8	Iyama T and Wilson DM 3rd: DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst). 12:620–636. 2013. View Article : Google Scholar : PubMed/NCBI
9	Kraguljac Kurtović N, Krajnović M, Bogdanović A, Suvajdžić N, Jovanović J, Dimitrijević B, Colović M and Krtolica K: Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: Association with a particular immunophenotype of blast cells. Med Oncol. 29:3547–3556. 2012. View Article : Google Scholar : PubMed/NCBI
10	Brandwein JM, Kassis J, Leber B, Hogge D, Howson-Jan K, Minden MD, Galarneau A and Pouliot JF: Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O (6)-methylguanine DNA methyltransferase expression. Br J Haematol. 167:664–670. 2014. View Article : Google Scholar : PubMed/NCBI
11	Fasan A, Alpermann T, Haferlach C, Grossmann V, Roller A, Kohlmann A, Eder C, Kern W, Haferlach T and Schnittger S: Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: A study on 623 cases. PLoS One. 8:e543652013. View Article : Google Scholar : PubMed/NCBI
12	Chen C, Wang L, Liao Q, Huang Y, Ye H, Chen F, Xu L, Ye M and Duan S: Hypermethylation of EDNRB promoter contributes to the risk of colorectal cancer. Diagn Pathol. 8:1992013. View Article : Google Scholar : PubMed/NCBI
13	Vidal DO, Paixão VA, Brait M, Souto EX, Caballero OL, Lopes LF and Vettore AL: Aberrant methylation in pediatric myelodysplastic syndrome. Leuk Res. 31:175–181. 2007. View Article : Google Scholar : PubMed/NCBI
14	Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, Peeh DM, Korn R, Stirn M, Carter CA, et al: Safety and activity of RRx-001 in patients with advanced cancer: A first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol. 16:1133–1142. 2015. View Article : Google Scholar : PubMed/NCBI
15	Malonia SK, Sinha S, Lakshminarasimhan P, Singh K, Jalota-Badhwar A, Rampalli S, Kaul-Ghanekar R and Chattopadhyay S: Gene regulation by SMAR1: Role in cellular homeostasis and cancer. Biochim Biophys Acta. 1815:1–12. 2011.PubMed/NCBI
16	Johannes Z, Ina Radtke, Timothy S, Pardee, Zhen Zhao, Amy R, Rappaport, Weijun Luo, Mila E, McCurrach, Yang MM, Dolan ME, Kogan SC, et al: Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 23:877–889. 2009. View Article : Google Scholar : PubMed/NCBI
17	Poddighe PJ, Wessels H, Merle P, Westers M, Bhola S, Loonen A, Zweegman S, Ossenkoppele GJ and Wondergem MJ: Genomic amplification of MYC as double minutes in a patient with APL-like leukemia. Mol Cytogenet. 7:672014. View Article : Google Scholar : PubMed/NCBI
18	Ofran Y and Rowe JM: Acute myeloid leukemia in adolescents and young adults: Challenging aspects. Acta Haematol. 132:292–297. 2014. View Article : Google Scholar : PubMed/NCBI
19	Pui CH: Acute leukemias with the t(4;11)(q21;q23). Leuk Lymphoma. 7:173–179. 1992. View Article : Google Scholar : PubMed/NCBI
20	Shahab F and Raziq F: Clinical presentations of acute leukemia. J Coll Physicians Surg Pak. 24:472–476. 2014.PubMed/NCBI